PLATINUM-SENSITIVE OVARIAN CANCER
Clinical trials for PLATINUM-SENSITIVE OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-SENSITIVE OVARIAN CANCER trials appear
Sign up with your email to follow new studies for PLATINUM-SENSITIVE OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to outperform chemo in ovarian cancer
Disease control Not yet recruitingThis phase 3 trial tests whether a new drug called mocertatug rezetecan (Mo-Rez) combined with bevacizumab works better than standard chemotherapy plus bevacizumab for women with platinum-sensitive ovarian cancer. The study includes about 690 participants whose cancer has returne…
Matched conditions: PLATINUM-SENSITIVE OVARIAN CANCER
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug cocktail shows promise for recurrent ovarian cancer
Disease control Not yet recruitingThis study tests a new drug combination for women with recurrent ovarian cancer that still responds to platinum chemotherapy. The treatment includes an immunotherapy (iparomlimab/tuvonralimab) plus standard chemo, followed by a maintenance drug (olaparib). The goal is to see if t…
Matched conditions: PLATINUM-SENSITIVE OVARIAN CANCER
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Can surgery buy more time for ovarian cancer patients?
Disease control Not yet recruitingThis study looks at whether a second surgery to remove visible tumors (secondary cytoreductive surgery) after chemotherapy helps women with platinum-sensitive recurrent ovarian cancer. About 160 participants will be randomly assigned to get surgery plus chemo or chemo alone. The …
Matched conditions: PLATINUM-SENSITIVE OVARIAN CANCER
Phase: PHASE2 • Sponsor: Asan Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC